Mizzou launches design phase for new nuclear research reactor

Mizzou launches design phase for new nuclear research reactor
by Clarence Oxford
Los Angeles CA (SPX) Apr 22, 2025

The University of Missouri has officially begun work on its cutting-edge research facility, NextGen MURR, with the signing of an initial agreement to design and license the new reactor. This marks the first step in what will be the university's largest capital investment to date.

In a major international collaboration, Mizzou has partnered with Hyundai Engineering America, the Korea Atomic Energy Research Institute (KAERI), Hyundai Engineering Company, and MPR Associates. These organizations bring a range of global expertise in research reactor development, engineering, construction, and nuclear licensing.

"This is a historic moment for our university, our state and the future of nuclear science and medicine," said University of Missouri President Mun Choi. "NextGen MURR represents our commitment to research that changes lives. It will allow Mizzou to lead the nation in producing critical medical isotopes while opening new frontiers in science, engineering and patient care."

NextGen MURR is being developed in response to a growing international need for medical radioisotopes, particularly those used in advanced diagnostics and cancer therapies. The project aims to solidify Missouri's role as a hub for nuclear medicine innovation, research, and manufacturing.

"The Board of Curators is proud to support this bold step forward," said Todd Graves, chair of the UM Board of Curators. "NextGen MURR is more than a reactor - it's an engine of progress. It will enhance Missouri's role as a leader in nuclear science medical research, economic development and education for generations to come."

The newly signed $10 million agreement covers the design studies phase, which will last approximately six months. During this time, the project team will conduct detailed programmatic assessments and site evaluations. This work will result in a roadmap outlining cost estimates and a proposed schedule for the full project. Once completed, the findings will inform a separate contract for the preliminary design and licensing phase, overseen by the Board of Curators and university leadership.

KAERI President Han Gyu Joo commented on the value of the partnership: "This remarkable partnership is made possible through the relentless dedication of experts involved in this project as well as the firm partnership between our two countries and people. Building upon this opportunity, we will work closely together with Mizzou for NextGen MURR, saving and improving lives."

Michael Hoehn II, program director for NextGen MURR, emphasized the long-term impact: "The new reactor will be designed to meet the needs of the future. From isotope production to advanced materials testing and workforce development, this reactor will be a platform for innovation that empowers the next generation of scientists, engineers and healthcare providers...and most importantly, improve the lives of U.S. patients. It's more than infrastructure - it's a strategic national asset in the making."

Consortium project executive In-cheol Lim added: "Throughout this project, we promise to honor Mizzou's core values - respecting our partners, taking responsibility, fostering discovery and striving for excellence at every step. We are committed to building a partnership rooted in trust, collaboration and shared purpose."

NextGen MURR will build upon the longstanding legacy of the university's current reactor, which remains the only U.S. facility producing key isotopes used in cancer treatments. The new facility will enhance the reliability of domestic radioisotope supply chains and enable continued breakthroughs in nuclear medicine.